The 36-month beta value for HURA is at 0.17. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HURA is 24.68M, and currently, shorts hold a 8.60% of that float. The average trading volume for HURA on July 02, 2025 was 230.67K shares.
HURA) stock’s latest price update
TuHURA Biosciences Inc (NASDAQ: HURA)’s stock price has plunge by 10.76relation to previous closing price of 2.23. Nevertheless, the company has seen a 5.11% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-01 that TAMPA, Fla., July 1, 2025 /PRNewswire/ — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the Company has been added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, as a part of the 2025 Russell indexes annual reconstitution.
HURA’s Market Performance
TuHURA Biosciences Inc (HURA) has seen a 5.11% rise in stock performance for the week, with a -19.28% decline in the past month and a -23.53% plunge in the past quarter. The volatility ratio for the week is 13.51%, and the volatility levels for the past 30 days are at 10.93% for HURA. The simple moving average for the past 20 days is -3.85% for HURA’s stock, with a -42.17% simple moving average for the past 200 days.
Analysts’ Opinion of HURA
Many brokerage firms have already submitted their reports for HURA stocks, with H.C. Wainwright repeating the rating for HURA by listing it as a “Buy.” The predicted price for HURA in the upcoming period, according to H.C. Wainwright is $13 based on the research report published on March 03, 2025 of the current year 2025.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see HURA reach a price target of $11. The rating they have provided for HURA stocks is “Buy” according to the report published on December 19th, 2024.
Maxim Group gave a rating of “Buy” to HURA, setting the target price at $15 in the report published on November 05th of the previous year.
HURA Trading at -24.12% from the 50-Day Moving Average
After a stumble in the market that brought HURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.09% of loss for the given period.
Stock Fundamentals for HURA
The total capital return value is set at -0.85. Equity return is now at value -244.16, with -174.44 for asset returns.
Based on TuHURA Biosciences Inc (HURA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -51.54. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -16.08.
Currently, EBITDA for the company is -17.43 million with net debt to EBITDA at 1.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In conclusion, TuHURA Biosciences Inc (HURA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
